Platelet Rich Plasma and Stem Cell Alopecia Treatment Market overview with detailed analysis, competitive landscape, forecast to 2026 – WhaTech…

Complete study of the global Platelet Rich Plasma and Stem Cell Alopecia Treatment market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape.

This report offers a clear understanding of the present as well as future scenario of the global Platelet Rich Plasma and Stem Cell Alopecia Treatment industry. Research techniques like PESTLE and Porters Five Forces analysis have been deployed by the researchers. They have also provided accurate data on Platelet Rich Plasma and Stem Cell Alopecia Treatment production, capacity, price, cost, margin, and revenue to help the players gain a clear understanding into the overall existing and future market situation.

Key companies operating in the global Platelet Rich Plasma and Stem Cell Alopecia Treatment market include _Kerastem, Eclipse, Regen Lab SA, Stemcell Technologies, RepliCel Life Sciences, Histogen, Glofinn Oy., ... Platelet Rich Plasma and Stem Cell Alopecia Treatment

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

http://www.qyresearch.com/index/dent-market

Segmental Analysis

The report has classified the global Platelet Rich Plasma and Stem Cell Alopecia Treatment industry into segments including product type and application. Every segment is evaluated based on growth rate and share. Besides, the analysts have studied the potential regions that may prove rewarding for the Platelet Rich Plasma and Stem Cell Alopecia Treatment manufcaturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overall Platelet Rich Plasma and Stem Cell Alopecia Treatment industry.

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Segment By Type:

, Androgenic Alopecia, Congenital Alopecia, Cicatricial Or Scarring Alopecia

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Segment By Application:

, Hospital, Dermatology Clinic, Other

Competitive Landscape

It is important for every market participant to be familiar with the competitive scenario in the global Platelet Rich Plasma and Stem Cell Alopecia Treatment industry. In order to fulfil the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key companies operating in the global Platelet Rich Plasma and Stem Cell Alopecia Treatment market include _Kerastem, Eclipse, Regen Lab SA, Stemcell Technologies, RepliCel Life Sciences, Histogen, Glofinn Oy., ...

Platelet Rich Plasma and Stem Cell Alopecia Treatment

Key questions answered in the report:

Enquire Customization in The Report: http://www.qyresearch.com/customient-market

TOC

1 Study Coverage1.1 Platelet Rich Plasma and Stem Cell Alopecia Treatment Product Introduction1.2 Market Segments1.3 Key Platelet Rich Plasma and Stem Cell Alopecia Treatment Manufacturers Covered: Ranking by Revenue1.4 Market by Type1.4.1 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Growth Rate by Type1.4.2 Androgenic Alopecia1.4.3 Congenital Alopecia1.4.4 Cicatricial Or Scarring Alopecia1.5 Market by Application1.5.1 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Growth Rate by Application1.5.2 Hospital1.5.3 Dermatology Clinic1.5.4 Other1.6 Coronavirus Disease 2019 (Covid-19): Platelet Rich Plasma and Stem Cell Alopecia Treatment Industry Impact1.6.1 How the Covid-19 is Affecting the Platelet Rich Plasma and Stem Cell Alopecia Treatment Industry1.6.1.1 Platelet Rich Plasma and Stem Cell Alopecia Treatment Business Impact Assessment - Covid-191.6.1.2 Supply Chain Challenges1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products1.6.2 Market Trends and Platelet Rich Plasma and Stem Cell Alopecia Treatment Potential Opportunities in the COVID-19 Landscape1.6.3 Measures / Proposal against Covid-191.6.3.1 Government Measures to Combat Covid-19 Impact1.6.3.2 Proposal for Platelet Rich Plasma and Stem Cell Alopecia Treatment Players to Combat Covid-19 Impact 1.7 Study Objectives 1.8 Years Considered 2 Executive Summary2.1 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Estimates and Forecasts2.1.1 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue 2015-20262.1.2 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales 2015-20262.2 Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size by Region: 2020 Versus 20262.2.1 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Retrospective Market Scenario in Sales by Region: 2015-20203.1 Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales by Manufacturers3.1.1 Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales by Manufacturers (2015-2020)3.1.2 Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales Market Share by Manufacturers (2015-2020)3.2 Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue by Manufacturers3.2.1 Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue by Manufacturers (2015-2020)3.2.2 Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue Share by Manufacturers (2015-2020)3.2.3 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Concentration Ratio (CR5 and HHI) (2015-2020)3.2.4 Global Top 10 and Top 5 Companies by Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue in 20193.2.5 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.3 Platelet Rich Plasma and Stem Cell Alopecia Treatment Price by Manufacturers3.4 Platelet Rich Plasma and Stem Cell Alopecia Treatment Manufacturing Base Distribution, Product Types3.4.1 Platelet Rich Plasma and Stem Cell Alopecia Treatment Manufacturers Manufacturing Base Distribution, Headquarters3.4.2 Manufacturers Platelet Rich Plasma and Stem Cell Alopecia Treatment Product Type3.4.3 Date of International Manufacturers Enter into Platelet Rich Plasma and Stem Cell Alopecia Treatment Market 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026)4.1 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size by Type (2015-2020)4.1.1 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales by Type (2015-2020)4.1.2 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue by Type (2015-2020)4.1.3 Platelet Rich Plasma and Stem Cell Alopecia Treatment Average Selling Price (ASP) by Type (2015-2026)4.2 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Forecast by Type (2021-2026)4.2.1 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales Forecast by Type (2021-2026)4.2.2 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue Forecast by Type (2021-2026)4.2.3 Platelet Rich Plasma and Stem Cell Alopecia Treatment Average Selling Price (ASP) Forecast by Type (2021-2026)4.3 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Breakdown Data by Application (2015-2026)5.1 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size by Application (2015-2020)5.1.1 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales by Application (2015-2020)5.1.2 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue by Application (2015-2020)5.1.3 Platelet Rich Plasma and Stem Cell Alopecia Treatment Price by Application (2015-2020)5.2 Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Forecast by Application (2021-2026)5.2.1 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales Forecast by Application (2021-2026)5.2.2 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue Forecast by Application (2021-2026)5.2.3 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Price Forecast by Application (2021-2026) 6 North America6.1 North America Platelet Rich Plasma and Stem Cell Alopecia Treatment by Country6.1.1 North America Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales by Country6.1.2 North America Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue by Country6.1.3 U.S.6.1.4 Canada6.2 North America Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Facts & Figures by Type6.3 North America Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Facts & Figures by Application 7 Europe7.1 Europe Platelet Rich Plasma and Stem Cell Alopecia Treatment by Country7.1.1 Europe Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales by Country7.1.2 Europe Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue by Country7.1.3 Germany7.1.4 France7.1.5 U.K.7.1.6 Italy7.1.7 Russia7.2 Europe Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Facts & Figures by Type7.3 Europe Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Facts & Figures by Application 8 Asia Pacific8.1 Asia Pacific Platelet Rich Plasma and Stem Cell Alopecia Treatment by Region8.1.1 Asia Pacific Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales by Region8.1.2 Asia Pacific Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue by Region8.1.3 China8.1.4 Japan8.1.5 South Korea8.1.6 India8.1.7 Australia8.1.8 Taiwan8.1.9 Indonesia8.1.10 Thailand8.1.11 Malaysia8.1.12 Philippines8.1.13 Vietnam8.2 Asia Pacific Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Facts & Figures by Type8.3 Asia Pacific Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Facts & Figures by Application 9 Latin America9.1 Latin America Platelet Rich Plasma and Stem Cell Alopecia Treatment by Country9.1.1 Latin America Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales by Country9.1.2 Latin America Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue by Country9.1.3 Mexico9.1.4 Brazil9.1.5 Argentina9.2 Central & South America Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Facts & Figures by Type9.3 Central & South America Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Facts & Figures by Application 10 Middle East and Africa10.1 Middle East and Africa Platelet Rich Plasma and Stem Cell Alopecia Treatment by Country10.1.1 Middle East and Africa Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales by Country10.1.2 Middle East and Africa Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue by Country10.1.3 Turkey10.1.4 Saudi Arabia10.1.5 U.A.E10.2 Middle East and Africa Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Facts & Figures by Type10.3 Middle East and Africa Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Facts & Figures by Application 11 Company Profiles11.1 Kerastem11.1.1 Kerastem Corporation Information11.1.2 Kerastem Description, Business Overview and Total Revenue11.1.3 Kerastem Sales, Revenue and Gross Margin (2015-2020)11.1.4 Kerastem Platelet Rich Plasma and Stem Cell Alopecia Treatment Products Offered11.1.5 Kerastem Recent Development11.2 Eclipse11.2.1 Eclipse Corporation Information11.2.2 Eclipse Description, Business Overview and Total Revenue11.2.3 Eclipse Sales, Revenue and Gross Margin (2015-2020)11.2.4 Eclipse Platelet Rich Plasma and Stem Cell Alopecia Treatment Products Offered11.2.5 Eclipse Recent Development11.3 Regen Lab SA11.3.1 Regen Lab SA Corporation Information11.3.2 Regen Lab SA Description, Business Overview and Total Revenue11.3.3 Regen Lab SA Sales, Revenue and Gross Margin (2015-2020)11.3.4 Regen Lab SA Platelet Rich Plasma and Stem Cell Alopecia Treatment Products Offered11.3.5 Regen Lab SA Recent Development11.4 Stemcell Technologies11.4.1 Stemcell Technologies Corporation Information11.4.2 Stemcell Technologies Description, Business Overview and Total Revenue11.4.3 Stemcell Technologies Sales, Revenue and Gross Margin (2015-2020)11.4.4 Stemcell Technologies Platelet Rich Plasma and Stem Cell Alopecia Treatment Products Offered11.4.5 Stemcell Technologies Recent Development11.5 RepliCel Life Sciences11.5.1 RepliCel Life Sciences Corporation Information11.5.2 RepliCel Life Sciences Description, Business Overview and Total Revenue11.5.3 RepliCel Life Sciences Sales, Revenue and Gross Margin (2015-2020)11.5.4 RepliCel Life Sciences Platelet Rich Plasma and Stem Cell Alopecia Treatment Products Offered11.5.5 RepliCel Life Sciences Recent Development11.6 Histogen11.6.1 Histogen Corporation Information11.6.2 Histogen Description, Business Overview and Total Revenue11.6.3 Histogen Sales, Revenue and Gross Margin (2015-2020)11.6.4 Histogen Platelet Rich Plasma and Stem Cell Alopecia Treatment Products Offered11.6.5 Histogen Recent Development11.7 Glofinn Oy.11.7.1 Glofinn Oy. Corporation Information11.7.2 Glofinn Oy. Description, Business Overview and Total Revenue11.7.3 Glofinn Oy. Sales, Revenue and Gross Margin (2015-2020)11.7.4 Glofinn Oy. Platelet Rich Plasma and Stem Cell Alopecia Treatment Products Offered11.7.5 Glofinn Oy. Recent Development11.1 Kerastem11.1.1 Kerastem Corporation Information11.1.2 Kerastem Description, Business Overview and Total Revenue11.1.3 Kerastem Sales, Revenue and Gross Margin (2015-2020)11.1.4 Kerastem Platelet Rich Plasma and Stem Cell Alopecia Treatment Products Offered11.1.5 Kerastem Recent Development 12 Future Forecast by Regions (Countries) (2021-2026)12.1 Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Estimates and Projections by Region12.1.1 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales Forecast by Regions 2021-202612.1.2 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue Forecast by Regions 2021-202612.2 North America Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Forecast (2021-2026)12.2.1 North America: Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales Forecast (2021-2026)12.2.2 North America: Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue Forecast (2021-2026)12.2.3 North America: Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Forecast by Country (2021-2026)12.3 Europe Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Forecast (2021-2026)12.3.1 Europe: Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales Forecast (2021-2026)12.3.2 Europe: Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue Forecast (2021-2026)12.3.3 Europe: Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Forecast by Country (2021-2026)12.4 Asia Pacific Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Forecast (2021-2026)12.4.1 Asia Pacific: Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales Forecast (2021-2026)12.4.2 Asia Pacific: Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue Forecast (2021-2026)12.4.3 Asia Pacific: Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Forecast by Region (2021-2026)12.5 Latin America Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Forecast (2021-2026)12.5.1 Latin America: Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales Forecast (2021-2026)12.5.2 Latin America: Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue Forecast (2021-2026)12.5.3 Latin America: Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Forecast by Country (2021-2026)12.6 Middle East and Africa Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Forecast (2021-2026)12.6.1 Middle East and Africa: Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales Forecast (2021-2026)12.6.2 Middle East and Africa: Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue Forecast (2021-2026)12.6.3 Middle East and Africa: Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Forecast by Country (2021-2026) 13 Market Opportunities, Challenges, Risks and Influences Factors Analysis13.1 Market Opportunities and Drivers13.2 Market Challenges13.3 Market Risks/Restraints13.4 Porters Five Forces Analysis13.5 Primary Interviews with Key Platelet Rich Plasma and Stem Cell Alopecia Treatment Players (Opinion Leaders) 14 Value Chain and Sales Channels Analysis 14.1 Value Chain Analysis14.2 Platelet Rich Plasma and Stem Cell Alopecia Treatment Customers 14.3 Sales Channels Analysis 14.3.1 Sales Channels 14.3.2 Distributors 15 Research Findings and Conclusion 16 Appendix 16.1 Research Methodology 16.1.1 Methodology/Research Approach 16.1.2 Data Source 16.2 Author Details

This email address is being protected from spambots. You need JavaScript enabled to view it.

Visit link:
Platelet Rich Plasma and Stem Cell Alopecia Treatment Market overview with detailed analysis, competitive landscape, forecast to 2026 - WhaTech...

Update: Pacific Beach Elementary student’s ongoing battle with leukemia – A few months ago we introduced you to Ace Pringle the first-grader from…

Ace, first-grader at Pacific Beach Elementary, and his 3-year-old younger brother, Crue.

A few months ago, we introduced you to Ace Pringle, the first-grader from Pacific Beach Elementary who is battling Multiple Phenotype Acute Leukemia. Since then, Ace has been going through chemotherapy treatments and hoping for remission.

Recently, Aces doctors recommended that he get a bone marrow transplant.

With a bone marrow transplant, the Pringle family has a few different options to get a donation. They could sign up for the national registry, look into stem cell research, or find a donor. Just this Tuesday, the Pringle family found out that Aces 3-year-old brother, Crue, is a perfect match.

These next steps are going to be difficult, but the fact that Crues a match is huge, says Ace and Crues mother, Amber Pringle. As I look at this rambunctious 3-year-old, he has no idea whats to come for him.

While Ace has been going through chemotherapy, COVID-19 has swept across the world; but the Pringle family did not need to change their lifestyle as the city shut down. When COVID-19 came, we were already living on lockdown. We were already wearing masks to the store, says Amber. Its interesting that everything has caught up with us. Its so surreal.

Additionally, the virus has brought a silver lining to Aces battle with leukemia. Ace has been able to join his first-grade class at PB Elementary with distance learning, says Aces father, John Pringle.

Ace was homeschooled before the San Diego Unified School District stopped in-person classes due to COVID-19. Now, because of the shift to online learning, Ace has been able to rejoin his first-grade class on Zoom.

Its been nice for Ace to join his classmates, says John Pringle. He enjoys connecting with all his classmates all on one screen.

Never would I have imagined that all the kids would have this opportunity to do online learning, adds Amber Pringle.

Although the COVID-19 pandemic has allowed Ace to learn with the rest of his class, the virus has had an adverse effect on his parents. John and Amber, both small business owners who put their careers on hold to care for Ace, were just getting back to work before the virus reached the city.

Over the past few months, the Pringle family has received assistance from family and friends. Weve really had a lot of support and were extremely thankful to everyone who has helped out, says John Pringle.

Like the rest of the city and the nation, the Pringle family are staying home and keeping safe. Additionally, they are celebrating the fact that Crue will play a crucial role in helping his brother. For now, the family hopes that Ace will soon be in remission so that they can go ahead with the bone marrow transplant.

To help support Ace and his family, consider donating on their GoFundMe page at gofundme.com/f/ace-pringle-leukemia-fundraiser.

More here:
Update: Pacific Beach Elementary student's ongoing battle with leukemia - A few months ago we introduced you to Ace Pringle the first-grader from...

130+ congressmen urge Trump to keep ban on aborted fetal tissue research in race for COVID-19 cure – Lifesite

WASHINGTON, DC, April 15, 2020 (LifeSiteNews) More than 130 members of Congress urged President Donald Trump to maintain your current fetal tissue research policy and to redirect funds toward ethical, successful alternatives to combat COVID-19.

The pro-life representatives, including House Minority Leader Kevin McCarthy, thanked Trump in an April 14 letter for his decisive actions to protect human life and human dignity on every front, praising him for having brought great hope to our nation.

In the wake of the coronavirus outbreak in the United States, it has been argued by some that Trumps ban on aborted fetal tissue research by government scientists is thwarting efforts to find a remedy for the disease.

A senior scientist at a government biomedical research laboratory has been thwarted in his efforts to conduct experiments on possible treatments for the new coronavirus because of the Trump administrations restrictions on research with human fetal tissue, the Washington Post claimed in March.

Several of the leading COVID-19 vaccine developments, however, are using aborted fetal cells.

15 state Attorneys General had written to President Trump on March 26, stating that the use of aborted fetal tissue could help accelerate vaccine development to combat COVID-19, as well as study the impact to pregnant women and children.

We ask you to end your Fetal Tissue Ban to allow our top scientists the ability to solve this global health crisis, the Attorneys General concluded.

The more than 130 pro-life members of Congress responded to the allegations brought forward by proponents of aborted fetal tissue research, pointing out that they repeat false claims and narratives which for many years have touted the utility of aborted fetal tissue in research, including the claim that aborted fetal tissue has been used to create many vaccines.

The signers of the April 14 letter stressed that fetal tissue from ongoing abortions has never been used in production of a single vaccine. Instead, a few old cell lines from abortions performed in the 1960s and 1970s are used for a small handful of vaccines.

More importantly, most vaccines today use more efficient, modern cell lines and production techniques, the members of Congress explained.

Also, the few attempted transplants of aborted fetal tissue have resulted in making most patients worse, not better, they added.

The members of Congress showed that scientific progress and ethical behavior can go hand in hand.

The focus of the current appeals for taxpayer money to buy fetal tissue is the supposed necessity of using aborted baby body parts to construct humanized mice to test drugs. Yet, this antiquated technology has been surpassed by a plethora of modern, ethical techniques, as has been thoroughly described and cited in Congressional testimony.

Accusing the proponents of aborted fetal tissue research of exploiting the current situation for their own benefit, the pro-life representatives said that holding the line ethically gives us the ability to put resources toward better, more promising science that is already showing potential against COVID-19.

They specifically mentioned three projects.

First, they pointed to humanized mice that already exist, but are not based on aborted fetal tissue.

Then, they talked about [r]epurposing already-approved drugs also showing potential in treating coronavirus patients. At the end of March, the Food and Drug Administration (FDA) authorized experimental coronavirus treatments using anti-malaria drugs chloroquine and hydroxychloroquine.

Finally, they emphasized the great potential of adult stem cells, derived without destroying embryos and without abortion. One specific type of human adult stem cell, they said, has been shown to generate new lung tissue and heal damaged lungs, essential for repair of lungs damaged by respiratory viruses. Another was successful in improving the health of people suffering from pneumonia induced by the coronavirus.

Instrumental in drafting the letter was Congressman Lawrence Lamborn, representing Colorados 5th congressional district since 2007.

During this crisis, the last thing anyone should do is try and advance the lefts radical abortion agenda, Lamborn said. Life is precious at all stages and any claim to the contrary is unconscionable.

He is convinced that a cure for COVID-19 will be found, but using tissue from aborted babies to do so is unethical and wrong. Im thankful that President Trump has taken such a strong stand for life, and Im confident a solution can be found while also maintaining the sanctity of life.

Marjorie Dannenfelser, president of pro-life Susan B. Anthony List, praised the letter in a statement on Wednesday.

As millions of Americans work together to fight the coronavirus outbreak, the profit-driven abortion industry and their allies exploit fears surrounding the pandemic to promote an extreme abortion agenda, she noted.

Abortion supporters insist that unethical experiments involving aborted baby body parts are necessary to find a cure for the coronavirus, ignoring the wide variety of ethical options already available and under development, she continued.

We are greatly encouraged by the strong leadership of Sen. Wicker, Sen. Cindy Hyde-Smith, Rep. Lamborn, Rep. Latta, and all our pro-life allies in Congress who are fighting back against the abortion industrys attempts to exploit this national pandemic to advance their dangerous agenda.

See the original post here:
130+ congressmen urge Trump to keep ban on aborted fetal tissue research in race for COVID-19 cure - Lifesite

The Global Peripheral Nerve Repair Devices Market is expected to grow from USD 5,396.43 Million in 2019 to USD 11,283.48 Million by the end of 2025 at…

New York, April 15, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Peripheral Nerve Repair Devices Market Research Report by Device, by Application, by End User - Global Forecast to 2025" - https://www.reportlinker.com/p05881975/?utm_source=GNW

"The Neurostimulation & Neuromodulation Device is projected to witness the highest growth during the forecast period"

On the basis of Device, the Peripheral Nerve Repair Devices Market is studied across Biomaterial and Neurostimulation & Neuromodulation Device. The Biomaterial further studied across Nerve Conduit, Nerve Connector, Nerve Protector, and Nerve Wrap. The Neurostimulation & Neuromodulation Device further studied across External Neurostimulation Device and Internal Neurostimulation Device. The Biomaterial commanded the largest size in the Peripheral Nerve Repair Devices Market in 2019. On the other hand, the Neurostimulation & Neuromodulation Device is expected to grow at the fastest CAGR during the forecast period.

"The Nerve Grafting is projected to witness the highest growth during the forecast period"

On the basis of Application, the Peripheral Nerve Repair Devices Market is studied across Direct Nerve Repair/Neurorrhaphy, Nerve Grafting, Neurostimulation & Neuromodulation Surgery, and Stem Cell Therapy. The Direct Nerve Repair/Neurorrhaphy further studied across Epineural Repair, Group Fascicular Repair, and Perineural Repair. The Nerve Grafting further studied across Allograft, Autograft, and Xenograft. The Stem Cell Therapy commanded the largest size in the Peripheral Nerve Repair Devices Market in 2019. On the other hand, the Nerve Grafting is expected to grow at the fastest CAGR during the forecast period.

"The Ambulatory Surgery Center is projected to witness the highest growth during the forecast period"

On the basis of End User, the Peripheral Nerve Repair Devices Market is studied across Ambulatory Surgery Center and Hospital & Clinic. The Hospital & Clinic commanded the largest size in the Peripheral Nerve Repair Devices Market in 2019. On the other hand, the Ambulatory Surgery Center is expected to grow at the fastest CAGR during the forecast period.

"The Asia-Pacific is projected to witness the highest growth during the forecast period"

On the basis of Geography, the Peripheral Nerve Repair Devices Market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region is studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region is studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region is studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. The Americas commanded the largest size in the Peripheral Nerve Repair Devices Market in 2019. On the other hand, the Asia-Pacific is expected to grow at the fastest CAGR during the forecast period.

Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Peripheral Nerve Repair Devices Market including Axogen Inc., Baxter International, Boston Scientific Incorporation, Cyberonics Inc., GlaxoSmithKline Pharmaceuticals Ltd., Integra LifeSciences Corporation, Medovent GmbH, Medtronic PLC, NeuroMetrix, Inc., Orthomed S.A.S., Polyganics B.V., Renerva, LLC,, St. Jude Medical, Stryker Corporation,, Synovis Micro Companies Alliance, Inc., and Toyobo Co., Ltd..

FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Peripheral Nerve Repair Devices Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on sulfuric acid offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:1. What is the market size and forecast of the Global Peripheral Nerve Repair Devices Market?2. What are the inhibiting factors and their impact analysis shaping the Global Peripheral Nerve Repair Devices Market during the forecast period?3. What is the competitive position if vendors in the Global Peripheral Nerve Repair Devices Market?4. How Porters Five Forces define the Global Peripheral Nerve Repair Devices Market landscape?5. What are the technology trends and regulatory frameworks in the Global Peripheral Nerve Repair Devices Market?6. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Peripheral Nerve Repair Devices Market?7. What is the competitive strategic window for opportunities in the Global Peripheral Nerve Repair Devices Market?8. What arRead the full report: https://www.reportlinker.com/p05881975/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Visit link:
The Global Peripheral Nerve Repair Devices Market is expected to grow from USD 5,396.43 Million in 2019 to USD 11,283.48 Million by the end of 2025 at...

Stem Cell Assay Market : Information, Figures and Analytical Insights 2019-2025 – Germany English News

Stem Cell Assay Market 2018: Global Industry Insights by Global Players, Regional Segmentation, Growth, Applications, Major Drivers, Value and Foreseen till 2024

The report provides both quantitative and qualitative information of global Stem Cell Assay market for period of 2018 to 2025. As per the analysis provided in the report, the global market of Stem Cell Assay is estimated to growth at a CAGR of _% during the forecast period 2018 to 2025 and is expected to rise to USD _ million/billion by the end of year 2025. In the year 2016, the global Stem Cell Assay market was valued at USD _ million/billion.

This research report based on Stem Cell Assay market and available with Market Study Report includes latest and upcoming industry trends in addition to the global spectrum of the Stem Cell Assay market that includes numerous regions. Likewise, the report also expands on intricate details pertaining to contributions by key players, demand and supply analysis as well as market share growth of the Stem Cell Assay industry.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/13462

Stem Cell Assay Market Overview:

The Research projects that the Stem Cell Assay market size will grow from in 2018 to by 2024, at an estimated CAGR of XX%. The base year considered for the study is 2018, and the market size is projected from 2018 to 2024.

Leading manufacturers of Stem Cell Assay Market:

The major players in the global stem cell assay market include GE Healthcare, Promega Corporation, Thermo Fisher Scientific Inc., Merck KGaA, Cell Biolabs, Inc., Hemogenix Inc., Stemcell Technologies Inc., Bio-Rad Laboratories Inc., R&D Systems Inc., and Cellular Dynamics International Inc.

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/13462

Some important highlights from the report include:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/13462

The Questions Answered by Stem Cell Assay Market Report:

And Many More.

Go here to read the rest:
Stem Cell Assay Market : Information, Figures and Analytical Insights 2019-2025 - Germany English News

Mesenchymal Stem Cells Market 2020-2026: Analysed by Business Growth, Development Factors, Applications, and Future Prospects – Science In Me

The Mesenchymal Stem Cells Market is expected to have a highly positive outlook for the next eight years 2019-2026. This Research Reports emphasizes on key industry analysis, market size, Share, growth and extensive industry dynamics with respect to drivers, opportunities, pricing details and latest trends in the industry.

The global Mesenchymal Stem Cells Market analysis further provides pioneering landscape of market along with market augmentation history and key development involved in the industry. The report also features comprehensive research study for high growth potential industries professional survey with market analysis. Mesenchymal Stem Cells Market report helps the companies to understand the market trends and future market prospective,opportunities and articulate the critical business strategies.

Apply Here For The Sample Copy Of The Report @ https://www.coherentmarketinsights.com/insight/request-sample/720

Geographical segmentation of Mesenchymal Stem Cells Market involves the regional outlook which further covers United States, China, Europe, Japan, Southeast Asia and Middle East & Africa. This report categorizes the market based on manufacturers, regions, type and application.

Mesenchymal Stem Cells Market: Competitive Landscape

Leading players operating in the global Mesenchymal Stem Cells Market include: Pluristem Therapeutics, LonzaThermo, Fisher, ATCC, Bio-Techne, MilliporeSigma, Genlantis, Celprogen, Cell Applications, PromoCell GmbH, Cyagen Biosciences, Human Longevity Inc., Axol Bioscience, Cytori Therapeutics, Eutilex Co.Ltd., ID Pharma Co. Ltd., BrainStrom Cell Therapeutics, Cytori Therapeutics Inc., Neovii Biotech, Angel Biotechnology, California Stem Cell Inc., Stemcelltechnologies Inc., and Celgene Corporation Inc.

Scope of the Report

The key features of the Mesenchymal Stem Cells Market report 2019-2026 are the organization, extensive amount of analysis and data from previous and current years as well as forecast data for the next five years. Most of the report is made up from tables, charts and figures that give our clients a clear picture of the Mesenchymal Stem Cells Market. The structure of Mesenchymal Stem Cells Market by identifying its various segments and sub-segments to help understanding the report.

Mesenchymal Stem Cells Market Research Report gives current competitive analysis and also valuable insights to clients/industries, which will assist them to prepare a new strategy to expand or penetrate in a global Mesenchymal Stem Cells Market.

As the report proceeds further, it covers the analysis of key market participants paired with development plans and policies, production techniques, price structure of the Mesenchymal Stem Cells Market. The report also identifies the other essential elements such as product overview, supply chain relationship, raw material supply and demand statistics, expected developments, profit and consumption ratio.

Get PDF Brochure for Research Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/720

Important Mesenchymal Stem Cells Market Data Available In This Report:

Buy This Research Study Report @ https://www.coherentmarketinsights.com/insight/buy-now/720

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

For More Related Reports: http://bit.ly/Rajkumar123

See the article here:
Mesenchymal Stem Cells Market 2020-2026: Analysed by Business Growth, Development Factors, Applications, and Future Prospects - Science In Me

Stem Cell Characterization Kits Market Prospects & Upcoming Trends and Opportunities Analyzed for Coming Years – The Cloud Tribune

Stem cells are biological cells that can be converted into specific type of cells as per the bodys requirement. Stem cells are of two types, i.e., adult stem cells and embryonic stem cells. Stem cells can be used to treat various diseases such as cancer, neurodegenerative disorder, cardiovascular disorder and tissue regeneration. Stem cell characterization is the initial step for stem cell research. Stem cell characterization is a challenging and also an evolving process. Stem cell characterization kits are used for identification of stem cell biology markers. In stem cell characterization, stem cell biology marker profiles differ based on their species, maturity and site of origin. Stem cell characterization kit is required to understand the utility of the stem cells in downstream experiments and to confirm the pluripotency of the stem cell.Request Free Sample Report-https://www.factmr.com/connectus/sample?flag=S&rep_id=2691

Based on type of stem cell, the stem cell characterization kits market is segmented into:Stem Cell Characterization Kits for Adult Stem CellsStem Cell Characterization Kits for Induced Pluripotent Stem CellsStem Cell Characterization Kits for Mesenchymal Stem CellsStem Cell Characterization Kits for Neural Stem CellsStem Cell Characterization Kits for Hematopoietic Stem CellsStem Cell Characterization Kits for Umbilical Cord Stem CellsStem Cell Characterization Kits for Human Embryonic Stem CellsBased on application, the stem cell characterization kits market is segmented into:ResearchDrug Discovery & DevelopmentRegenerative Medicine

Based on end user, the stem cell characterization kits market is segmented into:Biopharmaceutical CompaniesContract Research OrganizationsAcademics and Research InstitutesBiotechnology CompaniesHave Any Query? Ask our Industry Experts-https://www.factmr.com/connectus/sample?flag=AE&rep_id=2691

Examples of some of the key participants in the stem cell characterization kits market identified across the value chain include Merck KGaA, Celprogen, Inc., Creative Bioarray, Thermo Fisher Scientific Inc., BD Biosciences, R&D Systems, Inc., System Biosciences, Cosmo Bio USA, BioCat GmbH, and DS Pharma Biomedical Co., Ltd.Pertinent aspects this study on the Stem Cell Characterization Kits market tries to answer exhaustively are:

What is the forecast size (revenue/volumes) of the most lucrative regional market? What is the share of the dominant product/technology segment in the Stem Cell Characterization Kits market? What regions are likely to witness sizable investments in research and development funding? What are Covid 19 implication on Stem Cell Characterization Kits market and learn how businesses can respond, manage and mitigate the risks? Which countries will be the next destination for industry leaders in order to tap new revenue streams? Which new regulations might cause disruption in industry sentiments in near future? Which is the share of the dominant end user? Which region is expected to rise at the most dominant growth rate? Which technologies will have massive impact of new avenues in the Stem Cell Characterization Kits market? Which key end-use industry trends are expected to shape the growth prospects of the Stem Cell Characterization Kits market? What factors will promote new entrants in the Stem Cell Characterization Kits market? What is the degree of fragmentation in the Stem Cell Characterization Kits market, and will it increase in coming years?

Why Choose Fact.MR?

Fact.MR follows a multi- disciplinary approach to extract information about various industries. Our analysts perform thorough primary and secondary research to gather data associated with the market. With modern industrial and digitalization tools, we provide avant-garde business ideas to our clients. We address clients living in across parts of the world with our 24/7 service availability.

Link:
Stem Cell Characterization Kits Market Prospects & Upcoming Trends and Opportunities Analyzed for Coming Years - The Cloud Tribune

Stem Cell Therapy Market report edited by leading research firm – WhaTech Technology and Markets News

Global Stem Cell Therapy market report presents an overview of the market on the basis of key parameters such as market size, revenue, sales analysis and key drivers. The market size of global Stem Cell Therapy market is anticipated to grow at large scale over the forecast period (2020-2025).

The main purpose of the study report is to give users an extensive viewpoint of the market. So that users can apply strategic processes to benchmark themselves against rest of the world.

In addition, study report offers an array of opportunities for the players participating in the industry. This ultimately leads into the growth of the global Stem Cell Therapy market.

Furthermore, report offers a comprehensive study on market size, revenue, sales, growth factors and risks involved in the growth of the market during the forecast period. The factors which are influencing the growth the market are mentioned in the report as well as the challenges which can hamper the growth of the market over the forecast period.

The main objective of this research report is to present the comprehensive analysis about the factors which are responsible for the growth of the global Stem Cell Therapy market. The study report covers all the recent developments and innovations in the market for a Stem Cell Therapy.

The global keyword market is likely to provide insights for the major strategies which is also estimated to have an impact on the overall growth of the market. Several strategies such as the PESTEL analysis and SWOT analysis is also being covered for the global market.

These strategies have an impact on the overall market.

Browse the complete report @ http://www.adroitmarketresearch.com/industrapy-market

Global Stem Cell Therapy market is segmented based by type, application and region. Based on Type, the market has been segmented into:

Based on cell source, the market has been segmented into, Adipose Tissue-Derived Mesenchymal SCs Bone Marrow-Derived Mesenchymal SCs Embryonic SCs Other Sources

Based on application, the market has been segmented into:

Based on therapeutic application, the market has been segmented into, Musculoskeletal Disorders Wounds & Injuries Cardiovascular Diseases Gastrointestinal Diseases Immune System Diseases Other Applications

The research report on global Stem Cell Therapy market ensures users to remain competitive in the market. Also report helps to identify the new innovations and developments by existing key players to increase the growth of the global Stem Cell Therapy market.

Study report covers all the geographical regions where competitive landscape exists by the players such as North America, Europe, Latin America, Asia-Pacific and Middle East Africa. Thus report helps to identify the key growth countries and regions.

In addition, report presents quantitative as well as qualitative narration of global Stem Cell Therapy market. The research report is beneficial for educators, researchers, strategy managers, academic institutions and analysts.

Thus report helps all types of users to identify the strategic initiatives so that they can understand how to expand the global Stem Cell Therapy market business across the globe for the product development. Moreover, research report provides in depth analysis of all the segments which can impact on the market growth.

For Any Query on the Stem Cell Therapy Market: http://www.adroitmarketresearch.com/contactbuying/691

This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow this link:
Stem Cell Therapy Market report edited by leading research firm - WhaTech Technology and Markets News

Gracell to Present the First-in-human, Universal TruUCAR GC027 Therapy for Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia at the AACR…

SUZHOU, Chinaand SHANGHAI, April 13, 2020 /PRNewswire/ -- Gracell Biotechnologies Co., Ltd. ("Gracell"), a clinical-stage immune cell and gene therapy company, is pleased to announce that their first-in-human phase I data of Universal TruUCAR GC027 in relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) was accepted for plenary oral presentation at the America Association for Cancer Research (AACR) Annual Meeting.

This year's AACR presentations are moved to be held virtually to allow sharing the data in a timely fashion. A series of online sessions featuring presentations will be provided. Gracell will report the clinical safety and efficacy of GC027, an off-the-shelf CAR-T product based on Gracell's TruUCAR technology, for treatment of adult T-ALL patients.

"We are very pleased that AACR has accepted the phase I results of GC027, a first-in-human off-the-shelf TruUCAR product for plenary oral presentation. Gracell's proprietary TruUCAR platform was protected with patents of novel designs and unique features. Remarkably, GC027 derived from HLA unmatched donor's cells, is a monotherapy without co-administration of other immunosuppressive drug." said Dr. William CAO, founder and CEO of Gracell. "We are pleased to share thefirst-in-human phase I data with the scientific community."

Presentation: Safety and efficacy clinical study of TruUCART GC027: the first-in-human, universal CAR-T therapy for relapsed/refractory T-cell acute lymphoblastic leukemiaAbstract #9564Online live section: Apr. 27-28, EDT

About GC027GC027 was manufactured fromT cells of human leukocyte antigen (HLA) unmatched healthy donors using TruUCAR technology. TruUCAR allows the allogeneic CAR-T cells to proliferate and persist in HLA-unmatched patients (recipients) with minimized risk of graft-versus-host-disease (GvHD). GC027 is currently being developed as an investigational, off-the-shelf CAR-T cell therapy for treatment of T cell malignancies. The use of HLA unmatched healthy donor's cells may improve efficacy and reduce production time, available for off-the-shelf use in a timely manner.

About TruUCARTruUCAR is Gracell's proprietary and patented platform technology, with selected genes being edited to avoid GvHD and immune rejection without using strong immunosuppressive drugs. In addition to T-ALL antigen, the platform technology can also be implemented for other targets of hematological malignancies.

About T-ALLT - Lymphoblastic Leukemia (T-ALL) is an aggressive form of acute lymphoblastic leukemia, with a diffuse invasion of bone marrow and peripheral blood. In 2015, T-ALL affected around 876,000 people globally and resulted in 110,000 deaths worldwide. T-ALL compromises about 15%-20% of all children and adult acute lymphoblastic leukemia[1].Current standard of care therapies for T-ALL are chemotherapy and stem cell transplantation. 40-50% of patients will experience relapse within two years following front line therapy with limited treatment options available[2] [3]. Treatment of relapsed and refractory T-ALL remains a high unmet medical need.

About GracellGracell Biotechnologies Co., Ltd. ("Gracell") is a clinical-stage biotech company, committed to developing highly reliable and affordable cell gene therapies for cancer. Gracell is dedicated to resolving the remaining challenges in CAR-T, such as high production costs, lengthy manufacturing process, lack of off-the-shelf products, and inefficacy against solid tumors. Led by a group of world-class scientists, Gracell is advancing FasTCAR, TruUCAR (off-the-shelf CAR), Dual CAR and Enhanced CAR-T cell therapies for leukemia, lymphoma, myeloma, and solid tumors.

CONTACT:

Linc HEBusiness Development and Public RelationsLinc.he@gracellbio.com+86-21-6403-1375

[1] Pediatric hematologic Malignancies: T-cell acute lymphoblastic Leukemia, Hematology 2016[2] Progress and innovations in the management JAMA Oncol 2018[3] Defining the course and prognosis of adults with acute lymphoblastic leukemia, Cancer 2010

View original content to download multimedia:http://www.prnewswire.com/news-releases/gracell-to-present-the-first-in-human-universal-truucar-gc027-therapy-for-relapsed-or-refractory-t-cell-acute-lymphoblastic-leukemia-at-the-aacr-annual-meeting-301039311.html

SOURCE Gracell

Read the original:
Gracell to Present the First-in-human, Universal TruUCAR GC027 Therapy for Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia at the AACR...

LILLEY: Trudeau government needs to stop taking COVID orders from WHO – Toronto Sun

Some days it really does feel like Canada has farmed out its entire health policy during this COVID-19 crisis to the World Health Organization.

From the early days, answers to questions on testing, on the spread of the virus, on approving treatments or even rapid testing, have been to cite what the WHO recommends.

That is nothing short of a dereliction of duty by Canadas top health officials.

The latest example is the decision of Health Canada not to approve a cheap and rapid test for COVID-19, one made right here in Canada, because of what the WHO says. BTNX Inc. of Markham, Ont. makes a test that can have results in 15 minutes and costs just $10 a piece.

The test cant be used for early detection but can confirm COVID-19 for people who have been showing symptoms for several days. It also tests for anti-bodies to determine if someone has already had the disease and therefore is possibly immune.

Despite the sale of this test kit in the U.S., the U.K. and across Europe, Health Canada turned the company down this past week. As CBC reported, the company was rejected by Health Canada over the advice given by the WHO.

In an email to CBC News, Health Canada said it is following the advice of the World Health Organization, which does not currently recommend serological (blood) tests for clinical diagnosis, CBC reported on Sunday.

Let me get this straight: We have a company that can provide accurate results using a blood test and we wont use it because an international body in Geneva says no?

Can you imagine that being the case when Banting and Best discovered how to extract insulin and treat diabetics at their University of Toronto lab? Or the invention of Pablum to fight off malnutrition in the 1930s?

Would Canadian doctors and researchers have had breakthroughs in open heart surgery, stem cell transplants, vaccines for childhood diseases, gene therapies, treatments for stroke, cystic fibrosis, HIV and more if we had to simply follow WHO guidelines?

No, in fact, following the rules of a bureaucratic organization like the WHO is the opposite of what researchers do.

Im not for a moment advocating that Canada should ignore the WHO, should play no part in it. The WHO has a role to play but that role is not in setting health policy for Canada.

Were we a less developed country with a less robust medical system, without more than a century of continuously evolving medical research, then perhaps listening to the WHO first and following their advice would make sense. For Canada it does not, it slows things down, it stops innovation.

Could and should Canada be working in coordination with the WHO? Sure, but not following their orders. This is an organization that has already been shown to have been slow off the mark by believing misinformation from the Chinese government at the start of this outbreak.

Sadly, though, whether the answers have come from Health Canada bureaucrats, the chief medical officer, the health minister or the prime minister, too often what Canadians have been told is a series of WHO talking points.

Canada has the medical ingenuity, the depth of research and the quality of doctors needed to chart our own path that at times will follow the WHO and at other times diverge. When time is of the essence in finding better ways to test, better ways to treat and better ways to counter the spread of this virus, Ill take Canadian doctors over a United Nations body in far off Geneva any day.

Lets hope the Trudeau government starts realizing that they should trust and champion Canadas medical community as well.

blilley@postmedia.com

View original post here:
LILLEY: Trudeau government needs to stop taking COVID orders from WHO - Toronto Sun